Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.82
-0.47 (-3.07%)
Oct 22, 2025, 4:00 PM EDT - Market closed
Amylyx Pharmaceuticals Revenue
Amylyx Pharmaceuticals had revenue of $-249.00K in the twelve months ending June 30, 2025, down -100.08% year-over-year. In the year 2024, Amylyx Pharmaceuticals had annual revenue of $87.37M, down -77.06%.
Revenue (ttm)
$-249.00K
Revenue Growth
-100.08%
P/S Ratio
-6,348.64
Revenue / Employee
n/a
Employees
123
Market Cap
1.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AMLX News
- 6 days ago - AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders - GlobeNewsWire
- 6 weeks ago - Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock - Business Wire
- 6 weeks ago - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
- 6 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - Amylyx to stop development of rare brain disorder drug after trial failure - Reuters
- 2 months ago - Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) - Business Wire
- 2 months ago - Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire